A retrospective, real-world study of bleeding outcomes, weekly factor consumption doses, annualized factor costs in severe-type patients with hemophilia a before and after switching to extended half-life rFVIII-Fc prophylaxis
Latest Information Update: 04 Feb 2022
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
Most Recent Events
- 04 Feb 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition